Both Heterozygous and Homozygous Loss-of-Function JPH3 Variants Are Associated with a Paroxysmal Movement Disorder

Recently, a single patient with a homozygous truncating variant in JPH3 and a neurodevelopmental disorder involving paroxysmal dystonia was described.1 We report both a second individual with recessive disease and a family with a milder phenotype and autosomal dominant inheritance (Fig. 1A).

Patient one, now 15 years old, was born to first-cousin parents with no relevant family or perinatal history. Her mother was asymptomatic, but the medical history of her father was unavailable. Early infant milestones were normal, but she did not walk until 3 years old. At school, she was identified as having moderate intellectual disability and behavioral difficulties. From 6 months old, her mother noticed episodes of abnormal body stiffening. Over time, these evolved into two clear episode types. “Minor” episodes consisted of brief right or occasionally left hemidystonia, which occurred several times each week. “Major” episodes happened two or three times per month and lasted up to 30 minutes. After a similar onset, they progressed to involuntary flailing movements of all limbs, impaired responsiveness, dysarthria, aphasia, and drooling, sometimes associated with upward eye deviation. Although “major” episodes tended to be triggered by fatigue, there was no obvious trigger for “minor” episodes. A clinical diagnosis of alternating hemiplegia of childhood (AHC) was made. Neurological examination between episodes was unremarkable. There was no disease progression over time. There was no clinical response to levodopa, oxcarbazepine, flunarizine, trihexyphenidyl, topiramate, or gabapentin, although prolonged episodes could be terminated with buccal midazolam. Extensive investigation including brain magnetic resonance imaging, electroencephalogram (EEG) (with capture of episodes. Several different medications—carbamazepine, valproate, topiramate, acetazolamide, and trihexyphenidyl—proved ineffective. Her maternal grandmother had experienced lifelong episodes of orofacial dystonia and limb posturing and had never learned to read. Her mother reported episodes of orofacial dystonia triggered by alcohol and had a slight resting tremor. She had completed compulsory education. The only relevant variant identified on WGS was a novel heterozygous nonsense variant in JPH3 (NM020655.3:c.1014C>G; p.Tyr338*) shared by mother and daughter; grandmaternal DNA was unavailable (Fig. 1B).

JPH3 encodes junctophilin-3, a component of the junctional complex linking the plasma membrane with the endoplasmic reticulum in excitable cells.2 Expression is highest in the brain. Pathological heterozygous triplet-repeat expansion variants (believed to cause toxic intracellular accumulation of abnormal protein)3,4 occurs in Huntington-like disease type 2, characterized by adult-onset chorea, dementia and atrophy of the cortex, and basal ganglia.5 However, we believe that the disorder from either biallelic or heterozygous truncating variants is a distinct condition, mediated by loss of protein function rather than toxic accumulation, and so far, appears non-progressive in reported cases (Fig. 1C). The gene is predicted to be highly intolerant of loss-of-function,6 and in mice, both haploinsufficiency and knockout of JPH3 result in an abnormal motor phenotype.7 Although the association of the variably penetrant, heterozygous phenotype will require further confirmation in additional patients, JPH3 variants should be considered in patients with undiagnosed complex paroxysmal movement disorders.

Acknowledgments: We are grateful to the patients and their families for their participation. Prof. Kurian’s research group has benefited from grants from the National Institute for Health Research, Rosetrees Trust and the Sir Jules Thorn Trust.

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.29250

© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Key Words: alternating hemiplegia of childhood, dystonia, JPH3, paroxysmal movement disorder

*Correspondence to: Professor Manju Kurian, NIHR Research Professor and UCL Professor of Neurogenetics, Honorary Consultant Paediatric Neurologist, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, 20 Guilford Street, WC1N 1DZ, London, UK; E-mail: manju.kurian@ucl.ac.uk

Received: 21 June 2022; Revised: 9 August 2022; Accepted: 29 August 2022

LETTERS: NEW OBSERVATION
Dora Steel, BMBCh,1,2 Aikaterini Vezyroglou, MD,1,2 Katy Barwick, PhD,1 Martin Smith, MBBS,5 Julie Vogt, MD,4 Frances M. Gibbon, MB, ChB,5 J. Helen Cross, PhD,1,2 and Manju A. Kurian, PhD1,2*

1 Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, United Kingdom, 2 Department of Neurology, Great Ormond Street Hospital, London, United Kingdom, 3 Department of Paediatric Neurology, Oxford University Hospitals NHS Foundation Trust, London, United Kingdom, 4 West Midlands Regional Genetics Service, Birmingham Women and Children’s Hospital NHS Foundation Trust, Birmingham, United Kingdom, and 5 Noah’s Ark Children’s Hospital for Wales, Cardiff and Vale University Health Board, Cardiff, Wales, United Kingdom

Funding Information

Professor Kurian’s laboratory receives funding from the National Institute for Health Research and the Sir Jules Thorn Charitable Trust.

Data Availability Statement

We are unable to make patients’ full genomic data available under the terms of our ethical approval but are happy to share details of methods and laboratory or clinical results on request.

References


Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Author Roles


D.S.: 1A, 1C, 3A
A.V.: 1C, 3B
K.B.: 1C, 3B
M.S.: 3B
H.C.: 3B
M.A.K.: 1A, 1B, 3B

Financial Disclosures

None of the authors has any financial disclosures relevant to the research. Financial relationships are listed below. D.S. is employed by UCL with a salary paid by a grant from the National Institute for Health Research. A.V. is employed by UCL. K.B. is employed by UCL. M.S. is employed by the Oxford Radcliffe Hospitals National Health Service (NHS) Foundation Trust. J.V. is employed by the Birmingham Women and Children’s Hospitals NHS Foundation Trust. F.G. is employed by the Cardiff and Vale University Health Board. H.C. is employed by UCL with grants from various organizations. M.A.K. is employed by UCL. M.A.K.’s research group receives grants from the National Institute of Health Research; Rosetrees Fund; Great Ormond Street Hospital Charity; LifeArc; and the Sir Jules Thorn Trust.